Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Adagene $100 million at-the-market offering
We advised Adagene on the offering
Stoke Therapeutics $125 million stock and pre-funded warrants offering
The common stock is listed on the Nasdaq Global Select Market
AnHeart Therapeutics acquisition by Nuvation Bio
We are advising AnHeart Therapeutics on the acquisition
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Haleon $3.1 billion secondary offering
The shares are listed on the NYSE
Smith+Nephew $1 billion notes offering
We advised the issuer on the SEC-registered offering
Avid Bioservices $160 million convertible senior notes offering
The convertible notes are due 2029
REGENXBIO $140 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
iRhythm Technologies $661.25 million convertible senior notes offering
The 1.5% convertible senior notes are due 2029